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Abstract
Background: Paraoxonase (PON) has anti-atherogenic activity due to its protective function
against low density lipoprotein (LDL) oxidation. Alteration of enzyme activity due to
polymorphisms in the PON genes may influence the development of atheroma and thus affect
stroke risk. Three PON  genes (PON1,  PON2  and  PON3) have been identifiedand mapped to
chromosome 7.
Methods:  We looked at the distribution of paraoxonase polymorphisms and haplotype
arrangement in 397 Caucasian ischaemic stroke patients and 405 controls. We investigated 6
different common single nucleotide polymorphisms (SNP) in PON genes; two substitutions in PON1
["A/G": Gln (Q)/Arg (R)] at codon 192 and ["T/A": Leu (L)/Met (M)] at codon 55, two in PON2 at
codon 311 ["G/A": Cys (C)/Ser (S)] and codon 148 ["C/G": Ala (A)/Gly (G)] and two SNPs, both
"A" to "G" substitutions, in PON3 – intronic rs2074353, which we designated PON3-1 and [Ala (A)/
Ala (A)] at codon 99, designated as PON3-3. Dynamic Allele Specific Hybridisation (DASH) was
used as the genotyping assay. Haplotype analysis was performed using both PHASE and EHPLUS
programs.
Results: Genotype and allele frequencies were similar in cases and controls. Lipid profiles were
not influenced by PON genotype. Haplotype frequencies for the six loci (PON2-148, PON2-311,
PON3-3, PON3-1, PON1-55 and PON1-192) were estimated. Comparison of the two programs
showed a significant difference in haplotype arrangements with EHPLUS (p-value = 0.005) but not
with PHASE Ver.2 (p-value = 0.12). The 112211 (1 = frequent allele, 2 = rare allele) haplotype
arrangement was commoner in cases than controls (p = 0.015), and the 111121 haplotype was
commoner in controls (p = 0.006).
Conclusion: Our study did not identify a role for individual paraoxonase gene polymorphisms in
the pathogenesis of ischaemic stroke. Findings of haplotype differences should be confirmed in large
scale studies. The importance of using a well-validated haplotype analysis program is also
underlined.
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Background
Ischaemic stroke is a complex trait, with genetic influences
likely to work through various risk factors for cerebrovas-
cular disease. Hypertension and dyslipidemia are known
to influence atherosclerosis and thus predispose to ischae-
mic stroke. Although lipids are a weaker risk factor for
stroke than blood pressure or age, hyperlipidemia con-
tributes to stroke risk [1], while lipid lowering therapy sig-
nificantly reduces the risk of stroke [2]. Low HDL has also
been reported as a risk factor for ischaemic stroke [3].
Genes involved in lipid metabolism have been previously
studied in the stroke population. Some studies suggest
APOE*ε4 and APOE*ε2 alleles are associated with higher
risk and lower risk of ischaemic stroke respectively,
although this has not been confirmed in all studies [4,5].
Paraoxonase, a 45 kDa glycoprotein, is well known for its
ability to detoxify organophosphates [6]. The process of
atherosclerosis is thought to begin with inflammatory
changes at the endothelial level, and oxidated LDL is
believed to be pro-inflammatory. Oxidated lipids have
also been associated with progression of carotid athero-
sclerosis [7,8]. As an HDL associated protein, paraoxonase
protects LDL against oxidation [9], and thus may protect
against atherosclerosis [10].
The paraoxonase gene maps to chromosome 7 (q21-23)
and has three isoforms, PON1, PON2 and PON3 [11].
Some studies suggest PON polymorphisms might predis-
pose to CHD or ischaemic stroke [12-14], while other
studies are less conclusive [15]. PON1 has two common
polymorphisms at codon 192 [A/G: Gln (Q)/Arg (R)] and
55 [T/A: Leu(L)/Met (M)]. These have been shown to cor-
relate with enzyme activity [16,17]. Increased enzyme
activity has been associated with higher HDL levels in
some populations [18,19], but not in all studies [20]. The
PON 192 and 55 polymorphisms have been associated
with risk of ischaemic stroke in a small study of younger
adults [13] and older patients respectively [21]. There are
two common polymorphisms of the PON2 gene, PON2-
148 [C/G: Ala (A)/Gly (G)] and PON2-311 [C/G: Cys (C)/
Ser (S)], and the PON2-148 "G" (G variant) is associated
with higher fasting blood glucose in NIDDM patients
[22]. The PON2-311 "G" (S allele) has been associated
with coronary artery diseases in different populations
[23]. PON3 is thought to have a similar role to PON1[24].
The purpose of this study was to assess the distribution of
polymorphisms of the PON1, PON2 and PON3 genes in
well-phenotyped patients with ischaemic stroke and
matched control subjects, and to expand on previous
studies by examining haplotype distribution in these sam-
ples. We also examined the association between genotype
and full lipid profile for a subgroup of controls.
Methods
Subjects
After ethical committee approval and informed consent,
397 Caucasian patients with a diagnosis of ischemic
stroke were recruited over a period of 3 years. Four hun-
dred and five Caucasian individuals from the same region,
without any clinical cerebrovascular or overt cardiovascu-
lar disease and matched for age and sex were used as con-
trols. For a subgroup of controls (n = 181) detailed lipid
parameters including total cholesterol, VLDL-Cholesterol,
VLDL Triglyceride, IDL, LDL, HDL2, HDL3 were available
for comparison with PON genotypes.
On the basis of clinical, laboratory and radiological
parameters, all stroke cases were classified according to
Trial of Org 10172 in Acute Stroke Treatment (TOAST) cri-
teria [25] to determine stroke subtype (Table 1).
Markers and genotyping
DNA was extracted using Nucleon® DNA extraction kits.
5–10 ng DNA was amplified through Hot Start PCR pro-
tocol using Immolase Taq DNA polymerase®. We used dif-
ferent sets of primers for each SNP as follows:
1-PON1-192 (A/G):
PON1-192F: 5'-biotin-CTATTTTCTTGACCCCTACTTA-3'
PON1-192R: 5'-CGCTAAACCCAAATACATCTCC-3'
2-PON1-55 (T/A):
PON1-55F: 5'-biotin-CTGACAGAAACTGGCTCTGAAG-3'
PON1-55R: 5'-AAGCCAGTCCATTAGGTAGTAT-3'
3-PON2-311 (C/G):
PON2-311F: 5'-biotin-GGTTCTCCGCATCCAGAACATT-
3'
PON2-311R: 5'-AACTGTAGTCACTGTAGGCTTCTC-3'
4-PON2-148 (C/G):
Table 1: TOAST (Trial of Org 10172 in Acute Stroke Treatment) 
Classification of stroke patients
Subtype All Stroke Samples
Number %
Large Vessel Disease (LVD) 93 23.4%
Small Vessel Disease (SVD) 87 21.9%
Cardioembolic 99 25%
Other/Unclassified 118 29.7%
TOTAL 397 100%BMC Medical Genetics 2006, 7:28 http://www.biomedcentral.com/1471-2350/7/28
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PON2-148F: 5'-AGTGGAAATTTTTAAATTTGAAG-3'
PON2-148R: 5'-biotin-ACTGTTTTCAGATGCAACA-
GAGA-3'
5-PON3-rs2074353 (PON3-1, A/G):
PON3b-2074353F: 5'-biotin-TCTTCCTTTGTAGTGTGT-
TAGGAA-3'
PON3-2074353R: 5'-AATTTTTACATAACTCTTGAAACA-3'
6-PON3-rs2375003 (PON3-2, C/T):
PON3b-2375003F: 5'-biotin-CTGATCCCATGTAGAT-
TAAATA-3'
PON3-2375003R: 5'-CGCTAGAAATCAGTGGTGGATT-3'
7-PON3-rs1053275 (PON3-3, A/G):
PON3b-1053275F: 5'-biotin-TGTCAAATCCACCACT-
GATTTCTA-3'
PON3-1053275R: 5'-GAACAAAACCCAAGGGCACAAG-
3'
Of the three PON3  SNPs, only two SNPs [rs2074353
(PON3-1, A/G) and rs1053275 (PON3-3, A/G)] were con-
firmed in our population, with genotype frequencies in
Hardy Weinberg equilibrium. All other SNPs were also in
Hardy Weinberg equilibrium.
Genotyping assays for determining different alleles were
based on the Dynamic Allele Specific Hybridisation
(DASH) technique as described by the developers [26].
Data analysis
Association between markers and disease phenotype was
tested with Pearson χ2 test. Multiple Logistic Regression
was used to adjust for differences between samples in age,
sex, smoking and hypertension. ANOVA was used to test
for associations between lipid profiles and allelic distribu-
tion. Haplotype frequencies for the six loci (PON2-148,
PON2-311 PON3-3, PON3-1, PON1-55 and PON1-192)
were estimated for cases and controls, using and compar-
ing two different validated programs: EHPLUS and
PHASE Ver.2 [27,28].
Results
Demographic parameters are shown in Table 2. Allele fre-
quency for the six PON alleles investigated is shown in
Table 3.
There was no significant difference between cases and
controls by sex in genotype and allele frequencies. There
was no significant difference in genotype and allele fre-
quencies between cases and controls in terms of age strat-
ification (≥65 and <65 years).
There was no significant difference in genotype or allele
frequencies between cases and controls in the SVD group
or LVD group, other than a small association between the
GG genotype of PON3 and females with LVD (p = 0.03,
OR = 2). PON2-311 "CC" genotype (SS variant) was
higher in male cardioembolic (CE) stroke patients than in
male controls (p = 0.03, OR = 2.05).
There was no association between lipid profile (LDL,
HDL, total cholesterol/HDL ratio or triglycerides) and
PON genotype in the stroke population. We also studied
the association between PON genotype and full lipid pro-
file in 181 of the controls. No differences were found in
Table 2: Demographic parameters of cases and controls:
Cases (n = 397) Controls (n = 405)
Age (mean ± SD) 67.9 (± 11.5)* 67.2 (± 11.7)
Sex (M:F ratio) 1:1 1:1.3
Hypertension (%) 55.1 24.6
Total cholesterol (mmol/L) (mean ± SD) 5.6 (± 1.38)* 5.0 (± 2.0)
HDL (mmol/L) (mean ± SD) 1.21 (± 0.42)* 1.24 (± 0.6)
LDL (mmol/L) (mean ± SD) 3.65 (± 1.81)* 2.27 (± 1.49)
Triglycerides (mmol/L) (mean ± SD) 2.1 (± 1.6)* 1.9(± 1.1)
Atrial fibrillation 19.4% -
Diabetes mellitus** 14.9% 3.2%
Previous IHD 33.5% -
Carotid Stenosis (Out of 227 scanned, >50%, 
based on ACST criteria)
26% -
* Non significant differences between cases and controls.
** History of diabetes or confirmed laboratory diagnosis.BMC Medical Genetics 2006, 7:28 http://www.biomedcentral.com/1471-2350/7/28
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VLDL-Cholesterol, IDL, LDL, HDL2, HDL3, and total cho-
lesterol concentrations in females or males between dif-
ferent genotypes of PON1-192, PON1-55, PON2-148 or
PON3-1. VLDL-Triglyceride was higher in females with
"GG" PON3-3 genotype (VLDL: AA genotype 69.8, "AG"
genotype 77.8, "GG" genotype 116.0; p = 0.036).
Haplotype analysis was performed using PHASE version
2.02 and EHPLUS programs. The PHASE program [27],
resulted in reconstruction of 16 different haplotypes in
cases and controls. Overall haplotype frequencies in cases
and controls were not significantly different (p = 0.19).
However, some individual haplotypes were more fre-
quent in one group than the other. Overall, the 112211
haplotype (1= frequent allele, 2= rare allele) was present
at a higher frequency among cases than controls (16.62%
vs 12.35%, p-value = 0.015, OR = 1.42 (1.07–1.87)). In
contrast, 111121 was less frequent in cases than in con-
trols (2.27% vs 4.81%, p = 0.006, OR = 0.46 (0.26–0.81)).
There were also some differences in haplotype combina-
tion (genotype distribution) between cases and controls
as follows: the "112211, 112221" haplotype (cases
10.6%, controls 5.2%: p = 0.005), the "111111, 112221"
haplotype (cases 4%, controls 7.9%: p = 0.023).
We repeated analyses using EHPLUS [28] to compare hap-
lotype arrangements in cases and controls. With this
method, there was a significant difference (p = 0.005, df,
63) between groups. The most frequent haplotype in cases
was 112211 and in controls 111111, while with PHASE2
the commonest haplotype for both groups was 112221.
The EHPLUS program generated 64 different haplotypes
both in cases and controls but only 32 had a frequency of
more than 1%.
Discussion
PON1 and PON2 are possible candidate genes for athero-
sclerotic diseases, especially coronary heart disease
(CHD), but findings are inconsistent. In a recent meta-
analysis of 43 studies [29], the 5 largest studies estimated
the per-allele risk ratio at 1.05 for PON1-192 R (B) allele
and combined analyses of studies of the PON1-55 M and
PON2-311 C variants showed no significant overall asso-
ciations with CHD. This differs from a recent study [30],
not included in the meta-analysis, which suggested that
the picture remains complicated. While there have been
fewer studies in ischaemic stroke, there is some evidence
of a role for the PON1-192 RR (BB) genotype and also for
the PON1 (C-107T) allele in younger ischaemic stroke
patients [13,14,31]. A recently published study of 81
stroke patients and 2053 controls from the CARE study
also suggested a role for PON1-192 in predisposing to
stroke, with no association with polymorphisms of the
other  PON  genes. In contrast to this study, haplotype
analysis or stroke subtyping was not performed [32].
There is evidence that paraoxonase (PON1) phenotype
may predict vascular disease more accurately than geno-
type alone [33]. Due to logistical constraints in the current
study it was not possible to measure PON1 phenotype,
but future vascular studies should consider this.
As there are ethical difficulties in gaining consent from
incapacitated individuals, this is not a study based on inci-
dent stroke. It is acknowledged therefore that patients
with more severe stroke may not be included. However,
the TOAST classification has similar distribution to other
studies. The distribution of other vascular risk factors
shows that these are high risk individuals. They form a
subgroup of a Scottish stroke population which has been
demonstrated to have an association with 5-lipoxygenase
activating protein, an important mediator of the activity
of cellular 5-Lipoxygenase (5-LO) which is a key enzyme
in the biosynthesis of leukotrienes, and may thus be
involved in atherosclerosis by proinflammatory mecha-
nisms [34]. While a large number of individuals were
unclassifiable by TOAST criteria, they all had CT evidence
of ischaemic stroke. Individuals with cardioembolic
stroke were also included. While these individuals may
have a different underlying mechanism for their event, the
role of oxidative stress through lipids driving athero-
thrombosis is likely to underlie the cardiac disease in most
of these individuals.
Other than weak associations in small subgroups (females
with LVD stroke, males with CE stroke), our study found
no significance in overall allele or genotype frequency,
although haplotype analysis suggests that the combina-
tion of certain alleles may increase or decrease the risk of
Table 3: Allele Frequencies of 6 SNPs in PON2, PON3 &PON1 genes
PON2- PON3- PON1-
148 A/G 311 C/G 3 A/G 1 A/G 55 T/A 192 A/G
Patients (n = 397) 0.76/0.24 0.77/0.23 0.48/0.52 0.48/0.52 0.64/0.36 0.71/0.29
Controls (n = 405) 0.73/0.27 0.74/0.26 0.52/0.48 0.51/0.49 0.63/0.37 0.71/0.29
P-value 0.29 0.16 0.11 0.20 0.73 0.89
OR * (95% CI) 1.16 (0.88–1.52) 1.18 (0.94–1.48) 0.85 (0.69–1.04) 0.87 (0.71–1.07) 1.04 (0.84–1.27) 0.98 (0.79–1.22)
* Adjusted for age, sex and hypertension.BMC Medical Genetics 2006, 7:28 http://www.biomedcentral.com/1471-2350/7/28
Page 5 of 6
(page number not for citation purposes)
ischaemic stroke in the whole population or in some spe-
cific subtypes. These results should be interpreted with
caution due to the small numbers of individuals with spe-
cific haplotypes, but reinforces the need for very large
scale studies to provide a definitive answer.
Although there are several programs based on different
methods that can infer haplotypes, there is no consensus
as to which method is the best [35]. Most programs,
including EHPLUS, a modified version of EH developed
by Ott, use the EM (Expectation-Maximisation) algorithm
[28,35]. The program ignores all partial or missing geno-
type data so that the algorithm uses the full set of available
data.
The PHASE program is based on coalescent models and
uses Markov chain Monte Carlo methods [27,35]. These
algorithms use a population genetics model to estimate
different haplotype patterns, so a haplotype that is more
similar to the commonly observed haplotype patterns is
more likely to be inferred.
While the haplotype analysis is an important component
of association studies in complex diseases [36], and the
different computational methods have their individual
strengths and weaknesses, significant haplotype differ-
ences in the absence of genotypic or allelic differences are
difficult to interpret [35]. Our study highlights this further
since one method (EHPLUS) suggests a statistically signif-
icant difference while PHSE fails to demonstrate an over-
all significant difference. It remains unclear which
method is superior, but PHASE is believed to be more reli-
able for larger numbers of markers [35]. However, the
level of significance is modest and could have arisen by
chance.
In some genetic isolates certain PON genotypes can be
associated with variation in plasma lipoproteins levels
including LDL, HDL and total cholesterol [37-39]. In
addition the physical relationship of PON1 with HDL and
the existence of cholesterol pathway regulatory elements
at the PON1 locus suggest a further relationship of PON1
with lipoproteins, which may contribute to its role of vas-
cular diseases [40]. However, apart from a minor correla-
tion between VLDL-Triglyceride and PON3 genotypes in
female, we did not replicate these differences in our out-
bred Scottish population.
Conclusion
In conclusion, we found no significant genotypic or allelic
frequency differences between stroke cases and controls
for any of the structural polymorphisms of the PON genes
tested. We identified specific haplotypes which may influ-
ence stroke risk in our population. Further work is
required in large cohorts to determine whether these dif-
ferences are real or have arisen by chance.
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